When “Hormone Balance” Becomes a Supplement Stack

“Hormone balance” sounds like a treatment plan. Clinically, it can mean almost anything.

In this bonus episode of The Integrative Clinician, we start with a familiar patient: a 44-year-old with changing cycles, broken sleep, weight gain, low libido, irritability, and a growing stack of supplements she is taking for “hormone imbalance.”

Instead of asking what else she should add, we run the case through the B.R.I.D.G.E. clinical reasoning framework.

You’ll learn how to:

• Build two timelines: symptoms and interventions
•  Clear safety concerns before adding anything
•  Decide whether a lab will actually change your plan
•  Separate the menopause transition from competing drivers like thyroid disease, iron deficiency, sleep apnea, depression, medication effects, and nutrition gaps
•  Evaluate commonly used hormone-related supplements with more precision
•  Sequence interventions instead of stacking them
•  Give every product a clear disposition: continue, adjust, stop, or refer

We also look at DHEA, DIM, black cohosh, ashwagandha, and vitex, with an emphasis on what the evidence does and does not support, why preparation and formulation matter, and where safety considerations change the plan.

The goal is not to use fewer natural therapeutics.

It is to use them more intentionally, more individually, and more defensibly.

If you work with women in midlife and have ever inherited a supplement stack you did not create, this episode is for you.

Learn more about BridgeWell Integrative Education and the Natural Therapeutic Prescribing Series at bridgewelled.com.

About The Integrative Clinician by BridgeWell

The Integrative Clinician by BridgeWell is the podcast for nurse practitioners and NP students who want to practice differently.

Hosted by Dr. Sheri Erwin, DNP, MBA, APRN, FNP-C, each episode helps you develop the clinical reasoning, integrative medicine knowledge, and practical skills to care for patients with greater confidence. Whether you're exploring functional medicine, hormones, metabolic health, longevity medicine, or building your own integrative practice, you'll learn how experienced clinicians think and how to apply those principles in your own practice.

BridgeWell Integrative Education is more than education. It's the professional home for nurse practitioners who want to practice differently.

🌉 Learn more at www.bridgewelled.com

Follow and listen to The Integrative Clinician by BridgeWell:

Apple Podcasts
Spotify
Audible

If this episode helped you, please follow the show, leave a review on Apple Podcasts, and share it with another nurse practitioner who wants to practice differently.

Transcript

Copy Transcript Copied

0:00

Your patient is 44, her periods are changing, she is waking up at 3 a.m. She's gained weight around her middle section, her libido is down, she feels more irritable, and she tells you she just does not feel like herself anymore. And before she ever gets to your office, she has already started treating her hormone imbalance herself. DIM, DHEA, ashwagandha, maca, Magnesium, and maybe Vitex. And proprietary blend of supplements with a label promising hormone balance that contains eight more ingredients. And then she asks you, what else should I be taking? I want to ask a different question first. What exactly are we trying to treat? Because hormone balance sounds like a treatment goal. Clinically, it tells us almost nothing. And when six supplements are being used to treat one vaguely defined problem, what we have is probably not a treatment plan. We have a stack. Bridge. Six steps. I'm going to take them in order because the order is the whole point. B stands for build the clinical picture. R stands for recognize physiological patterns. I investigate strategically. D determine the primary driver. G, guide the plan with sequencing. E. Evaluate and iterate. Now notice where the product decision sits. It's the fifth step. Almost every supplement stack problem I see is a case where somebody started at G, guide the plan with sequencing. And I want to make something clear before we go any further. This is not an anti-supplement episode. There are nutrients and botanicals with legitimate roles in women's health. There are also patients for whom hormone therapy itself may be the appropriate treatment. The problem starts when the phrase, this balances hormones, takes the place of clinical reasoning that should have happened first. So let's build the clinical picture. B is yours. No test, no protocol, no product. Structured history and a timeline. And with this patient, there are actually two histories, not one. The first is her symptom history. She told you her hormones are all over the place. Okay, well, what does that really mean? Hot flashes, night sweats, heavy or irregular periods, premenstrual symptoms, insomnia, libido, vaginal or urinary symptoms, hair loss, acne, fatigue, weight gain, mood changes, those are not interchangeable clinical problems, and they don't necessarily share one cause. So get the timeline. What started first? What changed when? What happened in the months before it started? Now build the second timeline. What is she already taking? When did each product start? Why was it started? What was it supposed to do? And don't settle for a list that says dim magnesium hormone supplement. Ask her to bring the bottles or upload photographs of the labels, ingredient, dose, form, and start date. Those are the things you want to know. Because the answer to why are you taking dim is sometimes I don't really know. My last provider recommended it a couple of years ago, and I've been on it ever since then. And that is genuinely useful information, but her symptoms and her interventions are on the same timeline. You may be surprised how often that alone starts clarifying the picture before you order anything. Matching those two timelines really can be beneficial. So now let's move to R, recognize physiological patterns and clear safety first. R is where we begin sorting the presentation, and the rule we teach is safety clears first. For this patient, that starts with the presentation itself. Abnormal uterine bleeding at 44 deserves appropriate evaluation. It should not simply disappear into a hormone imbalance narrative. Postmenopausal bleeding, even more so. And if she tells you she's irritable, anxious, depressed, or simply doesn't feel like herself, screen appropriately. Perimenopause can overlap with meaningful changes in mental health, but that does not mean every mood symptom should automatically be treated as a hormone problem. Our role is to recognize it, screen it, and make sure the patient receives the appropriate level of care. Then look at the second source of potential safety issues. Her supplement cabinet. Before those products automatically stay in the plan, ask some basic questions. Does she have a history of hormone-sensitive cancer? Is she being treated for one now? Is she taking tamoxifen? Does she have a history of liver disease? Is she taking thyroid replacement or being treated for thyroid disease? Does she have autoimmune disease or taking immunosuppressive therapy? Could she be pregnant? And what other medications and supplements is she taking? Those questions matter because natural does not mean pharmacologically inactive. Take ashwagandha, for instance. There are documented cases of clinically apparent liver injury associated with its use, typically appearing within weeks of starting it. There are also signals that it can affect thyroid physiology, although we do not have evidence showing that it is destabilized levothyroxine doses. So for someone with thyroid disease or thyroid replacement therapy, that is a monitoring consideration, not a documented drug interaction. There are also immune activity signals, but we do not have outcome or interaction studies to establish what those mean in patients with autoimmune disease or those taking immune suppressants. Again, that's a precaution based on incomplete evidence, not a contraindication. And in pregnancy, avoidance is appropriate because adequate safety data are lacking, not because we have established that ashwagandha is not appropriate in pregnancy. Notice what we're doing here. We're separating known risk, potential risk, theoretical concern, and the absence of evidence. Those are not interchangeable. The distinction is part of evidence-informed integrative practice. Let's move on to I. Investigate strategically. I is not about what testing is available, and it isn't about what might be interesting. Let's use one test that gets ordered frequently in this population, DHEA-S. It comes back low. Suddenly the number becomes the diagnosis, the indication, and the treatment target. But that's not what the evidence supports. The Endocrine Society recommends against diagnosing androgen deficiency syndrome in otherwise healthy women based on androgen levels because there is no well-defined syndrome and the relationship between those levels and specific symptoms is poor. It also recommends against routinely prescribing DHEA simply because the level is low. So before you order a DHEA-S, ask, what will I do with each possible result? If the low result would not change your treatment plan in any way clinically, why are you ordering it? The same discipline belongs around specialty estrogen metabolite testing. Whatever you think about the physiology or methodology, ask the same question. Will this result change the diagnosis, treatment selection, or outcome monitoring in a meaningful way? A test does not become clinically useful simply because it produces more information. Let's move on to D. Determine the primary driver. This is where the phrase hormone imbalance really starts to break down.

Look at her symptoms again: 9:58

fatigue, weight gain, sleep disruption, low libido, mood changes, hair loss. Could menopause transition be contributing? Absolutely. But those symptoms also overlap with things like hypothyroidism, iron deficiency, obstructive sleep apnea, depression, medication effects, inadequate nutrition, and other conditions. So the question isn't, are hormones involved? The better question is, is the menopause transition the primary driver, a contributor, or a bystander? That distinction changes the plan, and mood symptoms are a perfect example. Research shows the risk of major depression changes during menopause transition, but you cannot read that risk from a single hormone level. At the same time, other studies suggest that hormonal variability and change, particularly in susceptible women, may matter. Those findings don't have to compete with each other. They tell us something more useful. A hormone level and a hormonal transition are not the same thing. And that's important when we talk about perimenopausal physiology. Perimenopause is not simply a period of steadily falling estrogen. Estradiol can remain normal or high and fluctuate substantially while ovulation becomes less reliable and the luteal progesterone declines. So when practitioners use the phrase estrogen dominance to describe relative estrogen exposure against declining progesterone, they may be pointing towards real physiology. But I want us to name the distinction correctly. Estrogen dominance is not a validated diagnosis. There is no established diagnostic criteria or validated serum ratio that turns that phrase into a clinical diagnosis. It is shorthand for physiological pattern, and the pattern is better named than labeled. Here's the reason I want you to carry this into practice. Two targeted interventions matched to an identified driver are far more clinically coherent than five generic interventions aimed at a label. Also, a six-product stack of supplements often tells me that D never happened. Let's look at G now, guide the plan with sequencing. Now and only now do we talk about products. And this is where I stop answering the question for you. I'll give you what we know, what we don't know, and where the boundaries are. You see the patient, you make the clinical decision, first define the job.

Every intervention should be doing one of three things: 13:03

replacement, treatment, or support. If she has a documented nutrient deficiency, you're replacing it. That's relatively straightforward. You know why you're using it and you have a target. You can reassess it. But many products marketed for hormone balance aren't replacing anything. They're being used because they may affect a pathway or improve a symptom. That can be a legitimate therapeutic strategy, but it's a different job with a different standard of evidence and a different way of deciding whether it worked. Let's take a look at DHEA. DHEA is an endogenous steroid hormone precursor, not another wellness vitamin. Systemic DHEA can increase downstream androgens and estrogen exposure. The evidence does not support routinely using oral DHEA simply because DHEA-S is low or as a general treatment for menopausal symptoms. Trials have also reported androgenic adverse effects, particularly acne, and keeping an important distinction clear, oral systemic DHEA is not the same intervention as vaginal prasterone. Vaginal progesterone has an established role for genitourinary syndrome of menopause. Evidence for the local therapy cannot simply be transferred to the oral DHEA. Same molecule family, different route, different indication, different evidence. That's the clinical reasoning. Now let's look at DIM. DIM is routinely recommended for estrogen detox and healthy estrogen metabolism. And here's where the evidence gets more interesting than either side of the argument usually makes it sound like. Human studies show that DIM can alter estrogen metabolite patterns, and dose appears to matter. So saying DIM doesn't affect estrogen metabolism would be inaccurate. But here's the question that matters clinically. Does changing the biomarker improve an outcome the patient actually cares about? That has not been established. What hasn't been established is that moving it improves a clinically and meaningful patient outcome. And for the patient sitting in front of you, there's an even more important gap. We do not have randomized trials establishing DIM as a treatment for the common perimenopausal symptoms for which it routinely recommends. So, yes, a physiology she has may include relative estrogen exposure against declining progesterone. That doesn't automatically establish that DIM improves it. And if she's taking tamoxifen, the conversation changes again. A randomized human trial found that DIM reduced concentrations of active tamoxifen metabolites. We do not yet know the clinical outcome significance of that pharmacokinetic interaction, but this is not merely theoretical. That is enough to make it clinically important and one more boundary. DIM is not endometrial protection. It should never be substituted for appropriate progesterone protection when that is indicated with systemic therapy. Black cohosh is a great example of why integrative clinicians need to remain up to date with their treatment options. The older evidence base was not particularly convincing, and the conclusion influenced major menopausal recommendations. Newer analyses have been more favorable, including evidence suggesting improvement in vasomotor and overall menopausal symptoms. Right now, the evidence isn't best described as black cohosh works or black cohosh doesn't work. There is genuine disagreement between evidence since this, with newer evidence trending more favorable. And there's another lesson here. Preparation matters. Different extracts and preparations are not automatically interchangeable. More is not necessarily better, and sourcing matters because authentication and adulteration have been documented concerns with black cohosh products. There is also liver injury signal that deserves appropriate caution and clear stop instructions, even though the relationship between the plant itself, individual susceptibility, and product quality is not simple. So the takeaway isn't fear the botanical. It's know the preparation, know the evidence, know the safety signal, and know what you're monitoring. So let's look at ashwagandha. ashwagandha gives us another important lesson. There is human trial evidence suggesting the benefit of certain stress-related and sleep outcomes. But look closely at what was actually studied. Specific extracts, specific doses, specific populations, and specific outcomes. A trial of one standardized ashwagandha extract does not automatically validate every product with ashwagandha printed on the front. And that's the principle I really want you to remember. Evidence inheritance is not transitive. Two bottles containing the same botanical, standardized differently, at different doses, studied for different outcomes, are not automatically interchangeable. Vitex, and Vitex briefly because it is in our patient's bag. It's recommended for everything from PMS to irregular cycles to progesterone support. Those aren't the same clinical claims. There may be evidence for certain premenstrual symptoms in certain populations. That doesn't validate every hormone claim attached to the product. And I'm not going further into vitex today because I haven't traced that evidence to the same level I have others. I'd rather tell you where the boundary of my evidence review is than fill the space with certainty I haven't earned. Sequencing, where the stack actually goes wrong. Now we get to what may be the most important part of G. Sequence is determined by physiological dependency, not by the length of the problem list. Some disturbances maintain others. If a downstream intervention isn't likely to work until an upstream problem is addressed, the upstream problem comes first. So the question isn't what needs attention? With this patient, several things may need attention. The question is what intervention has the greatest potential to change what comes next? If her sleep apnea is untreated, address it. If her ferritin is eight, that matters. If she is severely sleep deprived, drinking heavily every night, or eating in a way that cannot support her basic nutritional needs, another supplement doesn't make those things disappear. And this is why adding two products to an existing stack of six can destroy your ability to interpret anything. Four weeks later, she feels different, better in some ways, worse in other ways. What changed? The DIM, the DHEA, the Ashwagandha, her cycle, another medication? None of them? Change one variable that you choose deliberately and you get information. Change eight and you get a story. Borrow the discipline from pharmacology. If a patient presented with eight medications and new symptoms. You'd review the medication list before writing prescription number nine. Bring that same reflex here. Sometimes simplifying the plan tells you more than another test or another product. Let's move to the last letter in the bridge. E. Evaluate and iterate. You recommended something today. What should be different? And when? The reassessment point should come from the intervention you chose and the outcome you're treating. It isn't a one universal six-week or eight-week rule. Set the endpoint when you start. If you're treating hot flashes, are they less frequent or less disruptive? If you're targeting sleep, is sleep better? If you're replacing a documented deficiency, has the appropriate marker changed? Because I take this for hormones is not an endpoint. Neither is I've taken it for three years because somebody told me it was good for women. Every product should eventually end up in one of the four categories. There is a defined purpose for this product. The evidence reasonably supports the purpose the patient is taking this product. Is it safe alongside everything else she's taking? And it's either working or still within the intentionally selected trial period. That's your continue for questions. Now let's look at the adjust. The purpose is defensible, but the execution is not. It's the wrong preparation. A dose that doesn't reflect the evidence you're using. Product you can't adequately verify. Timing that interferes with another therapy. Keep the intervention if appropriate. Fix the implementation. The next is stop. There's no defined purpose for this product. The evidence doesn't support the purpose. There's a safety concern. The original indication has actually resolved. Or it received an adequate trial against a meaningful endpoint and it didn't work. And the last is refer. The problem is real, but someone else needs to be involved. Hormone-sensitive cancer history with questions about botanical therapy. Depression requiring treatment beyond what we're managing. A hormone therapy decision outside your scope or expertise. So the four are continue, adjust, stop, or refer. Every product should eventually have an answer. Here's your Monday challenge. Find a patient in your practice taking three or more products for hormone balance. Don't add anything. Run through the bridge. Build the two timelines, symptoms and interventions. Recognize what needs to clear first from a safety standpoint. Investigate only what actually changes your plan. And determine whether the menopause transition is the primary driver, the contributor, or the bystander. And then and only then look at the bottles. Pick one. Why is she taking it? What job does it do? Does the evidence support the job for this product in this patient? Where does it sit in the sequencing? How will you know if it's working? And when are you going to look again? Then give it a disposition. Is it to continue it, adjust it, stop it, or refer? And move to the next one. You may discover that every product has a defensible purpose. Great. You may also discover that nobody has asked these questions in two years. That's also useful information as well. I'll leave you with this. Integrative medicine gives us a broad therapeutic toolbox. And I think that's one of the greatest strengths. But a bigger toolbox raises the demand on clinical reasoning. The work isn't knowing the longest list of supplements, it's understanding the patient well enough to know which tools belong in their plan and which do not, and why. That's what Bridge is for. And it's why the product decision sits at step five instead of step one. And if this conversation is exactly the kind of clinical reasoning you want more of, keep an eye out for the natural therapeutic prescribing series from BridgeWell Integrative Education. It's a three-course series designed for nurse practitioners who want to move beyond simply knowing which supplements and natural therapeutics are commonly used and learn how to evaluate them with the same clinical discipline we bring to other therapeutic interventions. We'll look at the evidence, the formulation, and the dosing, safety and interactions, product quality, monitoring, and how to decide when the natural therapeutic actually belongs in the treatment plan. The three courses are being released individually. So depending on where you are and when you're listening, one, two, or all three may already be available. You can find the latest courses and resources at bridgewelled.com. And if you know another nurse practitioner who has ever inherited a patient with a bag full of hormone balancing supplements, send this episode to them. I'm Dr. Sheri Erwin. I'll see you next time on The Integrative Clinician.